<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30148062</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2212-1366</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>12</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of bone oncology</Title>                <ISOAbbreviation>J Bone Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>91-95</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbo.2018.07.011</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Bisphosphonate (BP) treatment to prevent bone loss in breast cancer patients is already well established. However, data on the association between oral BP exposure before cancer diagnosis and disease outcomes in patients with early breast cancer are still scarce. Limited information is available on alendronate, the most common oral agent for the treatment of post-menopausal osteoporosis, regarding the association with bone metastases.</AbstractText>                <AbstractText Label="Aim" NlmCategory="UNASSIGNED">To examine the association between oral bisphosphonate exposure before cancer diagnosis and the risk of bone metastases in osteoporotic women diagnosed with early breast cancer.</AbstractText>                <AbstractText Label="Subjects and methods" NlmCategory="UNASSIGNED">This historical cohort study was conducted at the oncology division at Tel Aviv Medical Center. The study population included post-menopausal women with early breast cancer, diagnosed between 2002 and 2012. Data on cancer characteristics, diagnosis of osteoporosis, prior bisphosphonate exposure and outcome were collected from medical files.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Among 297 osteoporotic women identified, 145 (49%) were treated with bisphosphonates (alendronate in 90% of the cases) before cancer diagnosis. BP-treated women were significantly older than the BP-naïve ones (67.9 years vs 64.6 years, <i>p</i> = 0.01), but comparable in risk factors and disease characteristics. Over a mean follow up of 5.6 years, nine cases of bone metastases were identified, eight of them among BP-naïve patient (cumulative incidence of 9.9%) and one among BP-treated patients (0.7%). In a multivariable Cox's proportional hazards survival model the use of BP prior to cancer diagnosis was associated with a hazard ratio of 0.04 (95%CI:0.004-0.403, <i>p</i> = 0.006) for bone metastasis. The HR remained similar after further adjustment for tumor stage and cancer therapy.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">History of alendronate use is associated with a lower likelihood of bone metastases in postmenopausal women with early breast cancer. Oral bisphosphonate treatment could be sufficient for reducing the risk of bone metastases.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rouach</LastName>                    <ForeName>Vanessa</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Weizmann 6', Tel Aviv, Israel.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>School of Public Health and Stanley Steyer Institute for Cancer Epidemiology and Research, Tel Aviv University, Israel.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goldshtein</LastName>                    <ForeName>Inbal</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Epidemiology &amp; Database Research, Maccabi Healthcare Services, Israel.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wolf</LastName>                    <ForeName>Ido</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Division, Tel Aviv Sourasky Medical Center, Israel.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Catane</LastName>                    <ForeName>Raphael</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Division, Sheba Medical Center, Israel.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chodick</LastName>                    <ForeName>Gabriel</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Epidemiology &amp; Database Research, Maccabi Healthcare Services, Israel.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>School of Public Health and Stanley Steyer Institute for Cancer Epidemiology and Research, Tel Aviv University, Israel.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Iton</LastName>                    <ForeName>Amit</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Sackler School of Medicine, Tel Aviv University, Israel.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stern</LastName>                    <ForeName>Naftali</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Weizmann 6', Tel Aviv, Israel.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cohen</LastName>                    <ForeName>Daniel</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>School of Public Health and Stanley Steyer Institute for Cancer Epidemiology and Research, Tel Aviv University, Israel.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>J Bone Oncol</MedlineTA>            <NlmUniqueID>101610292</NlmUniqueID>            <ISSNLinking>2212-1366</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2013 Feb;24(2):398-405</RefSource>                <PMID Version="1">23047045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2017 Jun 20;35(18):2062-2081</RefSource>                <PMID Version="1">28618241</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2015 Mar 14;385(9972):977-1010</RefSource>                <PMID Version="1">25467588</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2014 Aug;15(9):997-1006</RefSource>                <PMID Version="1">25035292</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2017 Apr 1;23(7):1684-1689</RefSource>                <PMID Version="1">27683176</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2006;8(2):R13</RefSource>                <PMID Version="1">16542503</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2011 Oct 13;365(15):1396-405</RefSource>                <PMID Version="1">21995387</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer Prev. 2013 Mar;22(2):112-20</RefSource>                <PMID Version="1">23361380</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Agents Med Chem. 2015;15(6):736-43</RefSource>                <PMID Version="1">25807940</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2011 Jul;12(7):631-41</RefSource>                <PMID Version="1">21641868</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2017 Jul 1;123(13):2444-2451</RefSource>                <PMID Version="1">28464211</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2001 Jan 1;19(1):10-7</RefSource>                <PMID Version="1">11134190</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2012 Jul;13(7):734-42</RefSource>                <PMID Version="1">22704583</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2012;7(7):e40783</RefSource>                <PMID Version="1">22844410</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drugs. 2017 Aug;77(12):1313-1336</RefSource>                <PMID Version="1">28616845</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cytokine Growth Factor Rev. 2011 Aug;22(4):221-9</RefSource>                <PMID Version="1">21924665</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2009 Feb 12;360(7):679-91</RefSource>                <PMID Version="1">19213681</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2015 Oct 3;386(10001):1353-1361</RefSource>                <PMID Version="1">26211824</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Metastasis Rev. 1989 Aug;8(2):98-101</RefSource>                <PMID Version="1">2673568</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Aug;164(3):537-555</RefSource>                <PMID Version="1">28503723</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2008 Dec;19(12):2007-11</RefSource>                <PMID Version="1">18664560</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Mar;65(2):87-108</RefSource>                <PMID Version="1">25651787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bone. 2011 Jan;48(1):71-9</RefSource>                <PMID Version="1">20655399</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 1999 Dec;5(12):3914-9</RefSource>                <PMID Version="1">10632320</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Biochem Biophys. 2014 Sep 15;558:70-8</RefSource>                <PMID Version="1">24976175</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Relat Cancer. 2006 Mar;13(1):7-26</RefSource>                <PMID Version="1">16601276</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2014 Oct 02;106(11):null</RefSource>                <PMID Version="1">25278509</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2011 Jun;11(6):411-25</RefSource>                <PMID Version="1">21593787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Care (Basel). 2017 Mar;12(1):21-28</RefSource>                <PMID Version="1">28611537</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Med. 2017 Oct;6(10):2271-2277</RefSource>                <PMID Version="1">28941210</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Alendronate</Keyword>            <Keyword MajorTopicYN="N">Bisphosphonates</Keyword>            <Keyword MajorTopicYN="N">Bone metastases</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30148062</ArticleId>            <ArticleId IdType="doi">10.1016/j.jbo.2018.07.011</ArticleId>            <ArticleId IdType="pii">S2212-1374(18)30049-6</ArticleId>            <ArticleId IdType="pmc">PMC6107893</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>